Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib-Reference-Cited by-同舟云学术

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib

Published:2013-03-28 Issue:6 Volume:88 Page:449-454
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Lee Sung-Eun¹,Choi Soo Young¹,Bang Ju-Hee¹,Kim Soo-Hyun¹,Jang Eun-jung¹,Byeun Ji-Young¹,Park Jin-Eok¹,Jeon Hye-Rim¹,Oh Yun Jeong¹,Kim Hyeoung-Joon²,Kim Yeo-Kyeoung²,Park Joon Seong³,Jeong Seong Hyun³,Kim Sung-Hyun⁴,Zang Dae Young⁵,Oh Sukjoong⁶,Koo Dong Hoe⁶,Kim Hawk⁷,Do Young Rok⁸,Kwak Jae-Yong⁹,Kim Jeong-A¹⁰,Kim Dae-Young¹¹,Mun Yeung-Chul¹²,Mauro Michael J.¹³,Kim Dong-Wook

Affiliation:

1. Cancer Research Institute, The Catholic University of Korea; Seoul; Korea

2. Department of Hematology-Oncology; Chonnam National University Hwasun Hospital; Hwasun; Korea

3. Department of Hematology-Oncology; Ajou University School of Medicine; Suwon; Korea

4. Department of Internal Medicine; Dong-A University College of Medicine; Busan; Korea

5. Department of Internal Medicine; Hallym University College of Medicine; Anyang; Korea

6. Division of Hematology-Oncology; Department of Internal Medicine; Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University; Seoul; Korea

7. Division of Hematology and Hematological Malignancies; Ulsan University Hospital, University of Ulsan college of Medicine; Ulsan; Korea

8. Division of Hematology-Oncology; School of Medicine; Keimyung University; Daegu; Korea

9. Division of Hematology-Oncology; Chonbuk National University Medical School; Jeonju; Korea

10. Department of Hematology, St. Vincent's Hospital; The Catholic University of Korea; Suwon; Korea

11. Department of Hematology; Asan Medical Center, University of Ulsan College of Medicine; Seoul; Korea

12. Department of Hematology; School of Medicine; Ewha Womans University; Seoul; Korea

13. Center for Hematologic Malignancies; Knight Cancer Institute; Oregon Health & Science University; Portland; Oregan

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23427/fullpdf

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings;Frontiers in Oncology;2023-04-05

2. Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia;Neoplasia;2022-10

3. Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3;Leukemia Research;2021-06

4. Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor‐discontinuation” in chronic myeloid leukemia;International Journal of Laboratory Hematology;2021-04-09

5. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial;Leukemia;2021-03-11